-
Professor Yao Zhu’s In-Depth Commentary on Precision Patient Selection and Novel T-Cell Engager Therapies
From November 10–16, 2025, the 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Academic Conference on Urologic and Male Genitourinary Tumors of the Sichuan Anti-Cancer Association were grandly held in Chengdu. The meeting brought together leading experts in urologic oncology from China and abroad, providing a high-level platform for academic exchange. During…
-
Professor Xiaolin Lu Offers an In-Depth Analysis of the BCG Dilemma and the Future of Novel Intravesical and Combination Immunotherapies
Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai, bringing together leading experts in urologic oncology from China and abroad. The meeting focused on bladder-sparing strategies for non–muscle-invasive bladder cancer (NMIBC), advances in novel intravesical agents, and the latest developments in immunotherapy. At the conference, Professor Xiaolin Lu from…
-
Professor Neal D. Shore: Enzalutamide Enables Early Intensification for High-Risk Biochemical Recurrence in Prostate Cancer
Editor’s Note: Prostate cancer is one of the most common malignancies in men. While prostate-specific antigen (PSA) monitoring remains a cornerstone for the early detection of biochemical recurrence (BCR), advances…
-
Professor Hao Zeng Shares MDT Strategies and Eight Key Surgical Scenarios for Non–Clear Cell Renal Cell Carcinoma
Highlights from the 15th Shanghai Urologic Oncology Academic Conference Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai, bringing together leading experts in urologic…
-
Building a New Collaborative Model for Urologic Oncology in the Yangtze River Delta
Advancing Long-Term Survival Strategies in Urologic Malignancies Highlights from the 15th Shanghai Urologic Oncology Academic Conference Editor’s Note: On December 12, 2025, the 15th Shanghai Urologic Oncology Academic Conference officially…
-
Professor Liang Aibin: Breaking Through Relapse and Resistance—Advancing Innovation in Dual-Target CAR-T Therapy | 2025 International Conference on Cell and Immunotherapy
To promote innovation in the fields of cell therapy and immunotherapy in China, facilitate in-depth discussion of key scientific challenges, and share the latest clinical research advances from a global perspective, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) was held in Hangzhou, China, from November 13–16, 2025. The meeting was jointly organized…
-
Voice of China at ASH | Professor Chen Wenming: Bispecific Antibodies and Other Innovative Therapies Advance the Treatment of RRMM, While Mass Spectrometry Optimizes Response Assessment
Relapsed/refractory multiple myeloma (RRMM) remains a major clinical challenge due to treatment resistance and poor prognosis, underscoring the urgent need for novel drugs and innovative therapeutic strategies. At the 2025 Annual Meeting of the American Society of Hematology (ASH), Professor Chen Wenming and his team from Beijing Chaoyang Hospital, Capital Medical University presented multiple innovative…
-
Fudan Cancer Center’s Urologic Team Pioneers a “Gradient Treatment” Model
Five-Year Survival Rates for Three Major Urologic Cancers Reach World-Class Levels, Bringing the “Chinese Approach” to Global Patients From record-breaking survival outcomes in precision-targeted therapy for urothelial carcinoma, to consecutive…
Connecting Medical Expertise through Media